Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Thromb Haemost. 2018 Aug 13;16(9):1779–1788. doi: 10.1111/jth.14233

Figure 3. Supraphysiologic fVIII replacement is required to reduce bleeding in fVIII−/− mice infused with weakly inhibitory anti-C1 MAb M6143.

Figure 3.

(A) Blood loss was measured in fVIII−/− mice infused with increasing doses of fVIII (180, 360, 720, or 1440 units/kg, corresponding to estimated peak plasma concentrations of 2.5, 5, 10, or 20 nM, respectively) or decreasing doses of MAb M6143 (0.5, 0.25, 0.13, or 0.06 mg/kg; corresponding to estimated peak plasma concentration of 65, 33, 16, or 8 nM, respectively). Data are presented as medians with IQR (n = 8 mice per group). Blood loss for each group was compared to fVIII−/− mice that received 2.5 nM fVIII alone using the Mann-Whitney U test, * p < 0.05, ** p < 0.01, or *** p < 0.001. (B) Concentration-dependent decrease in median blood loss in the tail snip bleeding model in fVIII−/− mice injected with 0.5 mg/kg (estimated peak plasma concentration 65 nM) MAb M6143 and increasing doses of fVIII.